- News
- Announcements
Announcements
Current & archive
Robotics and functional electrical stimulation for stroke rehabilitation
Robotic assisted rehabilitation (RAR) and functional electrostimulation (FES) can, among others, be used as a supplement to conventional rehabili-tation in post-stroke patients. The use of RAR could have the advantage of allowing more intensive and frequent therapy (by increasing the motiva-tion to train), which at the same time reduces the effort of the physiotherapist. FES is a targeted application of electrical stimulation inducing muscle contractions supporting motor activities. The electrical stimulation takes place during a functional movement and may, inter alia, strengthen the muscle and improve blood circulation or blood flow.
This report aimed at evaluating the additional clinical benefit of RAR and FES. Systematic reviews of effectiveness and safety were conducted in cooperation with a working group (ReMoS/ Rehabilitation of Mobility after Stroke - AG) of the Association of the Scientific Medical Societies in Germany (AWMF)
Publication: LBI-HTA Project Report No.: 128: https://eprints.aihta.at/1302
Contact: Gregor Goetz
Horizon Scanning in Oncology - Fact Sheets
Fact Sheet No. 41 (February 2021)
Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)
Fact Sheet No. 42 (February 2021)
Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
Fact Sheet No. 43 (February 2021)
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)
Covid-19: HSS/ Horizon Scanning Living Document (v12 March 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 38 (January 2021)
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)
Fact Sheet No. 39 (January 2021)
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 40 (January2021)
Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
Covid-19: HSS/ Horizon Scanning Living Document (v11 February 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Covid-19: HSS/ Horizon Scanning Living Document (v10 January 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our seven new HSO Fact Sheets.
Fact Sheet No. 31 (Dezember 2020)
Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma
Fact Sheet No. 32 (Dezember 2020)
Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer
Fact Sheet No. 33 (Dezember 2020)
Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis
Fact Sheet No. 34 (Dezember 2020)
Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer
Fact Sheet No. 35 (Dezember 2020)
Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)
Fact Sheet No. 36 (Dezember 2020)
Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer
Fact Sheet No. 37 (Dezember 2020)
Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer
Covid-19: HSS/ Horizon Scanning Living Document (v09 December 2020)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 28 (November 2020)
Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)
Fact Sheet No. 29 (November 2020)
Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)
Fact Sheet No. 30 ((November 2020)
A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer
